Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma

Cancer

Volumn 120, Issue 17, 2014, Pages 2766-2777

  Hou, Ya Chin ^a   Chao, Ying Jui ^a,b   Tung, Hui Ling ^b   Wang, Hao Chen ^b   Shan, Yan Shen ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

cancer stem cells; CD133; CD204; CD44; pancreatic ductal adenocarcinoma; tissue microarrays; tumor associated macrophages

Indexed keywords

CD133 ANTIGEN; CD204; CELL MARKER; HERMES ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; CANCER STEM CELL; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PREDICTION; PRIORITY JOURNAL; PROTEIN FUNCTION; SURVIVAL RATE; SURVIVAL TIME; TISSUE MICROARRAY; TUMOR ASSOCIATED LEUKOCYTE;

CANCER STEM CELLS; CD133; CD204; CD44; PANCREATIC DUCTAL ADENOCARCINOMA; TISSUE MICROARRAYS; TUMOR-ASSOCIATED MACROPHAGES;

ANTIGENS, CD; ANTIGENS, CD44; CARCINOMA, PANCREATIC DUCTAL; CELL COMMUNICATION; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; HUMANS; KAPLAN-MEIER ESTIMATE; MACROPHAGES; MALE; NEOPLASTIC STEM CELLS; PANCREATIC NEOPLASMS; PEPTIDES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SCAVENGER RECEPTORS, CLASS A; TUMOR MARKERS, BIOLOGICAL;

EID: 84906791750     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28774     Document Type: Article

References (40)

1. Hariharan D, Saied A, Kocher HM,. Analysis of mortality rates for pancreatic cancer across the world. HPB (Oxford). 2008; 10: 58-62.
2. Bilimoria KY, Bentrem DJ, Ko CY, et al. Validation of the 6th edition AJCC Pancreatic Cancer Staging System: report from the National Cancer Database. Cancer. 2007; 110: 738-744.
3. Siegel R, Naishadham D, Jemal A,. Cancer statistics, 2013. CA Cancer J Clin. 2013; 63: 11-30.
4. Michl P, Gress TM,. Current concepts and novel targets in advanced pancreatic cancer. Gut. 2013; 62: 317-326.
5. Abel EV, Simeone DM,. Biology and clinical applications of pancreatic cancer stem cells. Gastroenterology. 2013; 144: 1241-1248.
6. Visvader JE, Lindeman GJ,. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008; 8: 755-768.
7. Rasheed ZA, Yang J, Wang Q, et al. Prognostic significance of tumorigenic cells with mesenchymal features in pancreatic adenocarcinoma. J Natl Cancer Inst. 2010; 102: 340-351.
8. Maeda Qiang D, Shinchi H, et al. CD44 and CD133 expressions in primary tumor cells correlate to survival of pancreatic cancer patients [serial online]. Open Surg Oncol J. 2009; 1: 1-7.
9. Immervoll H, Hoem D, Sakariassen PO, et al. Expression of the "stem cell marker" CD133 in pancreas and pancreatic ductal adenocarcinomas [serial online]. BMC Cancer. 2008; 8: 48.
10. Immervoll H, Hoem D, Steffensen OJ, et al. Visualization of CD44 and CD133 in normal pancreas and pancreatic ductal adenocarcinomas: nonoverlapping membrane expression in cell populations positive for both markers. J Histochem Cytochem. 2011; 59: 441-455.
11. Steele CW, Jamieson NB, Evans TR, et al. Exploiting inflammation for therapeutic gain in pancreatic cancer. Br J Cancer. 2013; 108: 997-1003.
12. Biswas SK, Sica A, Lewis CE,. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol. 2008; 180: 2011-2017.
13. Talmadge JE, Donkor M, Scholar E,. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev. 2007; 26: 373-400.
14. Mantovani A, Schioppa T, Porta C, et al. Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev. 2006; 25: 315-322.
15. Traves PG, Luque A, Hortelano S,. Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game [serial online]. Mediators Inflamm. 2012: 568783, 2012.
16. Mantovani A, Sica A, Sozzani S, et al. The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 2004; 25: 677-686.
17. Shigeoka M, Urakawa N, Nakamura T, et al. Tumor associated macrophage expressing CD204 is associated with tumor aggressiveness of esophageal squamous cell carcinoma. Cancer Sci. 2013; 104: 1112-1119.
18. Hirayama S, Ishii G, Nagai K, et al. Prognostic impact of CD204-positive macrophages in lung squamous cell carcinoma: possible contribution of CD204-positive macrophages to the tumor-promoting microenvironment. J Thorac Oncol. 2012; 7: 1790-1797.
19. Fushimi S, Matsumoto M, Takahashi S, et al. Clinical significance of CD204-positive M2 macrophage in colorectal cancer. Virchows Arch. 2012; 461: S177-S178.
20. Kurahara H, Shinchi H, Mataki Y, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer [serial online]. J Surg Res. 2011; 167: e211-e219.
21. Mitchem JB, Brennan DJ, Knolhoff BL, et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013; 73: 1128-1141.
22. Miyazaki K, Maruyama T, Masuda H, et al. Stem cell-like differentiation potentials of endometrial side population cells as revealed by a newly developed in vivo endometrial stem cell assay [serial online]. PLoS One. 2012; 7: e50749.
23. Landis JR, Koch GG,. The measurement of observer agreement for categorical data. Biometrics. 1977; 33: 159-174.
24. Winter JM, Cameron JL, Campbell KA, et al. 1423 Pancreaticoduodenectomies for pancreatic cancer: a single-institution experience. J Gastrointest Surg 2006; 10: 1199-1210; discussion 1210-1211.
25. Reid-Lombardo KM, Fridley BL, Bamlet WR, et al. Survival is associated with genetic variation in inflammatory pathway genes among patients with resected and unresected pancreatic cancer. Ann Surg. 2013; 257: 1096-1102.
26. Lai LC, Cheong SK, Goh KL, et al. Clinical Practice Guidelines Committee on Tumour Markers of the Academy of Medicine of Malaysia. Clinical usefulness of tumour markers. Malays J Pathol. 2003; 25: 83-105.
27. Duffy MJ,. CA. 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem. 1998; 35 (pt 3): 364-370.
28. Sakahara H, Endo K, Nakajima K, et al. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer. 1986; 57: 1324-1326.
29. Camp RL, Charette LA, Rimm DL,. Validation of tissue microarray technology in breast carcinoma. Lab Invest. 2000; 80: 1943-1949.
30. Su Y, Shrubsole MJ, Ness RM, et al. Immunohistochemical expressions of Ki-67, cyclin D1, beta-catenin, cyclooxygenase-2, and epidermal growth factor receptor in human colorectal adenoma: a validation study of tissue microarrays. Cancer Epidemiol Biomarkers Prev. 2006; 15: 1719-1726.
31. Boone J, van Hillegersberg R, van Diest PJ, et al. Validation of tissue microarray technology in squamous cell carcinoma of the esophagus. Virchows Arch. 2008; 452: 507-514.
32. Sarkar FH, Li Y, Wang Z, et al. Pancreatic cancer stem cells and EMT in drug resistance and metastasis. Minerva Chir. 2009; 64: 489-500.
33. Galizia G, Gemei M, Del Vecchio L, et al. Combined CD133/CD44 expression as a prognostic indicator of disease-free survival in patients with colorectal cancer. Arch Surg. 2012; 147: 18-24.
34. Horst D, Kriegl L, Engel J, et al. Prognostic significance of the cancer stem cell markers CD133, CD44, and CD166 in colorectal cancer. Cancer Invest. 2009; 27: 844-850.
35. Ino Y, Yamazaki-Itoh R, Shimada K, et al. Immune cell infiltration as an indicator of the immune microenvironment of pancreatic cancer. Br J Cancer. 2013; 108: 914-923.
36. Clark CE, Hingorani SR, Mick R, et al. Dynamics of the immune reaction to pancreatic cancer from inception to invasion. Cancer Res. 2007; 67: 9518-9527.
37. Lesina M, Kurkowski MU, Ludes K, et al. Stat3/Socs3 activation by IL-6 trans-signaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell. 2011; 19: 456-469.
38. Wu A, Wei J, Kong LY, et al. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010; 12: 1113-1125.
39. Oguma K, Oshima H, Aoki M, et al. Activated macrophages promote Wnt signalling through tumour necrosis factor-alpha in gastric tumour cells. EMBO J. 2008; 27: 1671-1681.
40. Jinushi M, Chiba S, Yoshiyama H, et al. Tumor-associated macrophages regulate tumorigenicity and anticancer drug responses of cancer stem/initiating cells. Proc Natl Acad Sci U S A. 2011; 108: 12425-12430.